Opinion
Video
Switching to Biosimilars for the Management of Psoriasis
Author(s):
An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.
Video content above is prompted by the following:
- Why is it so critical to examine biosimilars in clinical trials?
- Discuss the importance of interchangeability and whether it is implemented in your clinical practice.
- What were the study methods for this interchangeability study?
- What were the key results seen in terms of pharmacokinetics, efficacy, and safety profile?
- How do you see the use of biosimilars evolving in the future for patients with psoriasis?
Related Videos
Related Content
